Xiaozhe Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaozhe Li has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Juan Li
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
3 shared publications - Lifen Kuang
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
3 shared publications - Meilan Chen
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
3 shared publications - Beihui Huang
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
2 shared publications - Jingli Gu
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
2 shared publications - Junru Liu
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
2 shared publications
Latest Publications
- Open Access
The Prognostic Significance of Dynamic Monitoring of Minimal Residual Disease Status in Patients with Multiple Myeloma: A Real-World Study
Background: Minimal residual disease (MRD) is an established prognostic factor in multiple myeloma (MM), but the significance of dynamic MRD changes before and after autologous stem cell transplantation (ASCT) remains unclear. Methods: We retrospectively analysed 335 newly diagnosed MM patients who underwent upfront ASCT. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence interval (CI), adjusting for clinical risk factors. Results: Patients were classified as having persistent MRD negativity (n = 82, 24.5%), MRD− to MRD+ conversion (n = 40, 11.9%), MRD+ to MRD− conversion (n = 168, 50.1%), or persistent MRD positivity (n = 45, 13.4%). Median OS was not reached: 105, 131, and 87 months for the groups (p < 0.001); and PFS was not reached: 50, 71, and 38 months (p < 0.001). In multivariable analysis, persistent MRD positivity (HR, 4.762; 95% CI, 2.151–10.546; p < 0.001) and MRD− to MRD+ conversion (HR, 3.925; 95% CI, 1.791–8.598; p < 0.001) were associated with increased mortality risk compared with persistent MRD negativity, whereas MRD+ to MRD− conversion showed a borderline-significant increase (HR, 1.973; 95% CI, 0.963–4.046; p = 0.063). In addition, similar patterns were observed for PFS. In subgroup analyses, late MRD+ to MRD− conversion was associated with inferior PFS (HR, 1.857; 95% CI, 1.136–3.034; p = 0.014), whereas MRD− to MRD+ conversion showed no differences in OS or PFS (all p > 0.05). Among persistent MRD-positive patients, stable or increasing MRD pattern predicted worse outcomes (HR, 4.397; 95% CI, 1.190–16.240; p = 0.026). Conclusions: Longitudinal MRD trajectories provided independent prognostic information beyond static MRD assessment in MM. Subgroup analyses further suggest that dynamic MRD assessment might help refine risk stratification after ASCT.
Open AccessThe Prognostic Significance of Dynamic Monitoring of Minimal Residual Disease Status in Patients with Multiple Myeloma: A Real-World Study
Background: Minimal residual disease (MRD) is an established prognostic factor in multiple myeloma (MM), but the significance of dynamic MRD changes before and after autologous stem cell transplantation (ASCT) remains unclear. Methods: We retrospectively analysed 335 newly diagnosed MM patients who underwent upfront ASCT. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence interval (CI), adjusting for clinical risk factors. Results: Patients were classified as having persistent MRD negativity (n = 82, 24.5%), MRD− to MRD+ conversion (n = 40, 11.9%), MRD+ to MRD− conversion (n = 168, 50.1%), or persistent MRD positivity (n = 45, 13.4%). Median OS was not reached: 105, 131, and 87 months for the groups (p < 0.001); and PFS was not reached: 50, 71, and 38 months (p < 0.001). In multivariable analysis, persistent MRD positivity (HR, 4.762; 95% CI, 2.151–10.546; p < 0.001) and MRD− to MRD+ conversion (HR, 3.925; 95% CI, 1.791–8.598; p < 0.001) were associated with increased mortality risk compared with persistent MRD negativity, whereas MRD+ to MRD− conversion showed a borderline-significant increase (HR, 1.973; 95% CI, 0.963–4.046; p = 0.063). In addition, similar patterns were observed for PFS. In subgroup analyses, late MRD+ to MRD− conversion was associated with inferior PFS (HR, 1.857; 95% CI, 1.136–3.034; p = 0.014), whereas MRD− to MRD+ conversion showed no differences in OS or PFS (all p > 0.05). Among persistent MRD-positive patients, stable or increasing MRD pattern predicted worse outcomes (HR, 4.397; 95% CI, 1.190–16.240; p = 0.026). Conclusions: Longitudinal MRD trajectories provided independent prognostic information beyond static MRD assessment in MM. Subgroup analyses further suggest that dynamic MRD assessment might help refine risk stratification after ASCT.
- Open Access
Sustained MRD Negative for 4 Years Is a Significant Marker of Prognosis in Patients with High-Risk Multiple Myeloma
Background/Objectives: The optimal duration of maintaining minimal residual disease (MRD) negative status remains unclear in transplant-eligible newly diagnosed multiple myeloma (TE-NDMM). This single-center retrospective study aimed to explore the minimum duration of sustained MRD negativity with prognostic value. Methods: This research included 223 TE-NDMM patients who achieved at least two consecutive MRD-negative assessments after initial treatment. We analyzed the influence of sustained MRD negativity on survival in different risk stratifications. Results: There was no difference in progression-free survival (PFS) between high-risk (HR) patients with an MRD negativity duration of ≥2 years and patients in the standard-risk (SR) group (70.77 vs. 67.38 months, p = 0.529). In SR patients, PFS showed no significant difference between patients maintaining MRD negativity for 2–3 years and those maintaining MRD negativity for more than 3 years (72.25 months vs. 107.50 months, p = 0.103). In contrast, in the HR group, there was no difference between a duration of 4–5 years and ≥5 years (NR vs. 84.53 months, p = 0.136). A duration over 2 years was associated with superior overall survival (OS) for all patients. Conclusions: Long-term maintenance of MRD-negative status was associated with good prognosis. Sustained MRD negativity for ≥2 years was associated with reducing the adverse influence of high-risk cytogenetics, and a duration over 4 years may be correlated with longer PFS in high-risk multiple myeloma patients in an exploratory analysis based on limited cases.
Open AccessSustained MRD Negative for 4 Years Is a Significant Marker of Prognosis in Patients with High-Risk Multiple Myeloma
Background/Objectives: The optimal duration of maintaining minimal residual disease (MRD) negative status remains unclear in transplant-eligible newly diagnosed multiple myeloma (TE-NDMM). This single-center retrospective study aimed to explore the minimum duration of sustained MRD negativity with prognostic value. Methods: This research included 223 TE-NDMM patients who achieved at least two consecutive MRD-negative assessments after initial treatment. We analyzed the influence of sustained MRD negativity on survival in different risk stratifications. Results: There was no difference in progression-free survival (PFS) between high-risk (HR) patients with an MRD negativity duration of ≥2 years and patients in the standard-risk (SR) group (70.77 vs. 67.38 months, p = 0.529). In SR patients, PFS showed no significant difference between patients maintaining MRD negativity for 2–3 years and those maintaining MRD negativity for more than 3 years (72.25 months vs. 107.50 months, p = 0.103). In contrast, in the HR group, there was no difference between a duration of 4–5 years and ≥5 years (NR vs. 84.53 months, p = 0.136). A duration over 2 years was associated with superior overall survival (OS) for all patients. Conclusions: Long-term maintenance of MRD-negative status was associated with good prognosis. Sustained MRD negativity for ≥2 years was associated with reducing the adverse influence of high-risk cytogenetics, and a duration over 4 years may be correlated with longer PFS in high-risk multiple myeloma patients in an exploratory analysis based on limited cases.
- Open Access
- 9 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 145
Early Identification of the Non-Transplanted Functional High-Risk Multiple Myeloma: Insights from a Predictive Nomogram
Background: Patients with multiple myeloma (MM) who have a suboptimal response to induction therapy or early relapse are classified as functional high-risk (FHR) patients and have been shown to have a dismal prognosis. The aim of this study was to establish a predictive nomogram for patients with non-transplanted FHR MM. Materials and Methods: The group comprised 215 patients in our center between 1 January 2006 and 1 March 2024. To identify independent risk factors, univariate and multivariate logistic regression analyses were performed, and a nomogram was constructed to predict non-transplant FHR MM. To evaluate the nomogram’s predictive accuracy, we utilized bias-corrected AUC, calibration curves, decision curve analysis (DCA), and clinical impact curves (CIC). Results: Multivariate logistic regression demonstrated that younger age at onset, a higher proportion of LDH (more than 220 U/L), pattern A + C of M protein decline patterns, a lower proportion of patients with induction treatment efficacy than VGPR, and those undergoing maintenance therapies were independent risk factors for patients with non-transplanted FHR MM. The AUC scores for the training and internal validation groups were 0.940 (95% CI 0.893–0.986) and 0.978 (95% CI 0.930–1.000). DCA and CIC curves were utilized to further verify the clinical efficacy of the nomogram. Conclusions: We developed a nomogram that enables early prediction of non-transplant FHR MM patients. Younger age at onset, LDH ≥ 220 U/L, an A + C pattern of M-protein decline, and induction therapy efficacy not reaching VGPR are more likely to be FHR MM patients. Patients who do not undergo maintenance therapy are prone to early progression or relapse.
- 9 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 145
Open AccessEarly Identification of the Non-Transplanted Functional High-Risk Multiple Myeloma: Insights from a Predictive Nomogram
Background: Patients with multiple myeloma (MM) who have a suboptimal response to induction therapy or early relapse are classified as functional high-risk (FHR) patients and have been shown to have a dismal prognosis. The aim of this study was to establish a predictive nomogram for patients with non-transplanted FHR MM. Materials and Methods: The group comprised 215 patients in our center between 1 January 2006 and 1 March 2024. To identify independent risk factors, univariate and multivariate logistic regression analyses were performed, and a nomogram was constructed to predict non-transplant FHR MM. To evaluate the nomogram’s predictive accuracy, we utilized bias-corrected AUC, calibration curves, decision curve analysis (DCA), and clinical impact curves (CIC). Results: Multivariate logistic regression demonstrated that younger age at onset, a higher proportion of LDH (more than 220 U/L), pattern A + C of M protein decline patterns, a lower proportion of patients with induction treatment efficacy than VGPR, and those undergoing maintenance therapies were independent risk factors for patients with non-transplanted FHR MM. The AUC scores for the training and internal validation groups were 0.940 (95% CI 0.893–0.986) and 0.978 (95% CI 0.930–1.000). DCA and CIC curves were utilized to further verify the clinical efficacy of the nomogram. Conclusions: We developed a nomogram that enables early prediction of non-transplant FHR MM patients. Younger age at onset, LDH ≥ 220 U/L, an A + C pattern of M-protein decline, and induction therapy efficacy not reaching VGPR are more likely to be FHR MM patients. Patients who do not undergo maintenance therapy are prone to early progression or relapse.